Attorney Docket No.: 67824.407222

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior listings of claims in the application:

LISTING OF CLAIMS:

1-234 were cancelled in an Amendment dated January 11, 2005.

Claims 235-286 are cancelled herein in favor of new claims 287-338.

287. (New) A method for identifying a compound that putatively modulates taste .in a

human subject based on its effect in T1R1 polypeptide activation comprising:

(i) screening one or more compounds in a functional assay that detects

compounds which activate or modulate (enhance or inhibit) the activation of a human T1R1

polypeptide selected from the group consisting of:

(a) a TIRI polypeptide having the amino acid sequence contained in SEQ.

ID. NO: 17;

(b) a human T1R1 polypeptide that possesses at least 90% sequence

identity to the polypeptide contained in SEQ. ID. NO: 17 that specifically binds to a ligand that

also specifically binds to the T1R1 polypeptide contained in SEQ ID NO:17;

(c) a human T1R1 polypeptide which is encoded by a nucleic acid

sequence that hybridizes to the T1R1 polypeptide coding region of the nucleic acid sequence

contained in SEQ. ID. NO: 15 or 16 under stringent hybridization conditions which are 50%

contained in 524, 1271, 67 to 17

formamide, 5X SCC and 1% SDS, incubating at 42 degrees C and wash in 0.2X SSC and 0.1% SDS at 65 degrees C and which T1R1 polypeptide that specifically binds to a taste ligand that

specifically binds to the T1R1 polypeptide contained in SEQ ID NO:17; and

Attorney Docket No.: 67824,407222

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

(ii) identifying compounds that putatively modulate taste in a human subject

based on their (a) activation or modulation (inhibition or enhancement) of the activation of said

T1R1 polypeptide according to (a), (b), or (c), in said functional assay (i).

288. (New) The method of claim 287, wherein said T1R1 polypeptide has the amino acid

sequence contained in SEQ. ID. NO: 17.

289. (New) The method of claim 287, wherein said T1R1 polypeptide has an amino acid

sequence that possesses at least 90% sequence identity to the polypeptide contained in SEQ. ID.

NO: 17.

290. (New) The method of claim 287, wherein said T1R1 polypeptide has an amino acid

sequence that possesses at least 95% sequence identity to the polypeptide contained in SEQ. ID.

NO: 17.

291. (New) The method of claim 287, wherein said T1R1 polypeptide has an amino acid

sequence that possesses at least 96% sequence identity to the polypeptide contained in SEQ. ID.

NO: 17.

292. (New) The method of claim 287, wherein the T1R1 polypeptide possesses at least

97% sequence identity to the polypeptide contained in SEQ. ID. NO: 17.

293. (New) The method of claim 287, wherein said T1R1 polypeptide has an amino acid

sequence that possesses at least 97% sequence identity to the polypeptide contained in SEQ. ID.

NO: 21.

Attorney Docket No.: 67824.407222

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

294. (New) The method of claim 287, wherein said TIR2 polypeptide has an amino acid

sequence that possesses at least 98% sequence identity to the polypeptide contained in SEQ. ID.

NO: 17.

295. (New) The method of claim 287, wherein said T1R1 polypeptide has an amino acid

sequence that possesses at least 99% sequence identity to the polypeptide contained in SEQ. ID.

NO: 17.

296. (New) The method of claim 287, wherein said T1R1 polypeptide is encoded by a

nucleic acid sequence that hybridizes to the T1R1 coding region contained in SEQ. ID. NO: 20

under stringent hybridization conditions.

297. (New) The method of claim 287, wherein said T1R1 polypeptide comprises a

functional fragment of the polypeptide contained in SEQ. ID. No: 17.

298. (New) The method of claim 287, wherein said T1R1 polypeptide is expressed in a

cell.

299. (New) The method of claim 298, wherein said cell is intact or permeabilized.

300. (New) The method of claim 287, wherein said T1R1 polypeptide is comprised in a

membrane extract.

301. (New) The method of claim 298, wherein said T1R1 polypeptide is expressed on the

surface of said cell.

302. (New) The method of claim 298, wherein the cell is a prokaryotic cell.

303. (New) The method of claim 298, wherein the cell is a eukaryotic cell.

Attorney Docket No.: 67824.407222

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

304. (New) The method of claim 298, wherein said cell is a yeast, insect, amphibian or mammalian cell.

305. (New) The method of claim 298, wherein the cell is a CHO, HEK-293, COS or Xenopus oocyte.

- 306. (New) The method of claims 298, wherein said cell expresses a G protein.
- 307. (New) The method of claim 306, wherein said G protein is  $G_{\alpha 15}$  or  $G_{\alpha 16}$  or gustducin.
- 308. (New) The method of claim 287, wherein said functional assay detects the effect of said compound on phosphorylation of the TIR2 polypeptide.
- 309. (New) The method of claim 287, wherein the functional assay detects the effect of said compound on the dissociation of said TIR2 polypeptide and a G protein.
- 310. (New) The method of claim 287, wherein the functional assay detects the effect of said compound on arrestin translocation.
- 311. (New) The method of claim 287, wherein the functional assay detects the effect of said compound on second messenger(s).
- 312. (New) The method of claim 287, wherein the functional assay detects the effect of said compound on signal transduction.
- 313. (New) The method of claim 287, wherein the functional assay is a fluorescent polarization assay.

Attorney Docket No.: 67824.407222

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

315. (New) The method of claim 287, wherein said functional assay detects changes in cAMP, cGMP or IP3.

316. (New) The method of claims 287, wherein said functional assay detects changes in intracellular calcium.

317. (New) The method of claim 316, which uses a calcium-sensitive dye.

318. (New) The method of claim 287 which detects the effect of said compound on G protein activation by said T1R1 polypeptide.

319. (New) The method of claim 318, wherein said G protein is  $G_{\alpha 15}$ ,  $G_{\alpha 16}$  or gustducin.

320. (New) The method of claim 287, wherein said T1R1 polypeptide in said functional assay is stably or transiently expressed by a cell.

321. (New) The method of claim 287, wherein the functional assay detects changes in ionic polarization of a cell or membrane that expresses the T1R1 polypeptide.

322. (New) The method of claim 321, wherein ion polarization is detected by a voltageclamp or patch-clamp method.

323. (New) The method of claim 287, wherein said functional assay comprises a radiolabeled ion flux assay or fluorescence assay that detects T1R1 activity using a voltagesensitive dye.

324. (New) The method if claim 287, wherein said assay comprises a fluorescent polarization or FRET assay.

Attorney Docket No.: 67824,407222 (Formerly 54072D2)

Response Dated January 11, 2007 In Response to the Office Action of October 11, 2006

325. (New) The method of claim 287, wherein said assay detects changes in adenylate

cyclase activity.

326. (New) The method of claim 287, wherein the functional assay detects changes in

ligand-dependent coupling of said T1R1 polypeptide with a G protein.

327. (New) The method of claim 326, wherein said G protein is  $G_{\alpha 15}$  or  $G_{\alpha 16}$  or gustducin.

328. (New) The method of claim 287, wherein said functional assay detects changes in

intracellular cAMP or cGMP.

329. (New) The method of claim 287, wherein said assay measures the effect of said

compound on transmitter or hormone release.

330. (New) The method of claim 287 wherein said functional assay detects the effect of

said compound on the transcription of a gene of interest.

331. (New) The method of claim 330, wherein said gene is a reporter selected from

chloramphenicol acetyltransferase, luciferase, 3'-galactosidase and alkaline phosphatase.

332. (New) The method of claim 287, wherein the functional assay is a high throughput

assay.

333. (New) The method of 332, wherein said functional assay screens a library of

compounds.

334. (New) The method of claim 333, wherein said library is a combinatorial chemical

library.

Attorney Docket No.: 67824.407222 (Formerly 54072D2)

(Formerly 54072D2) Response Dated January 11, 2007

In Response to the Office Action of October 11, 2006

335. (New) The method of claim 333, wherein said library comprises at least 1000 compounds.

- 336. (New) The method of claim 287, wherein the effect of said putative taste modulator is further assayed in vivo for its effect on taste.
- 337. (New) The method of claim 336 which is used to assay the effect of said compound on the taste of a particular compound.
- 338. (New) The method of claim 336, wherein said assay is used to detect the effect of said compound on sweet or umami taste.